NCT02534636View on ClinicalTrials.gov

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Healthy Subjects
Interventions
DRUG

BMS-986165

DRUG

Interferon alpha-2a recombinant

DRUG

Famotidine

OTHER

Placebo

Trial Locations (1)

3004

Local Institution, Melbourne

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY